These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

Benzinga

2025/05/07

CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.

The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.

“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”

CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.

These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.
Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.

Considering buying CRSP stock? Here’s what analysts think:

Read This Next:

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533987747"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533987747\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533987747?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533987747","market":"hk","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-05-07 20:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/25/05/45250973/these-analysts-slash-their-forecasts-on-crispr-therapeutics-following-q1-results","article_id":"2533987747","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533987747","pubTimestamp":1746621581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LENZ":"Therapeutics","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4611":"AI医疗","BK4139":"生物科技","CRSP":"CRISPR Therapeutics AG"},"translate_title":"这些分析师在第一季度业绩公布后大幅下调了对CRISPR Therapeutics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"LENZ":1},"content_text":"CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.\nThe company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.\n“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”\nCRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.\nThese analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.\n\nChardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.\nNeedham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.\n\nConsidering buying CRSP stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Energy Stocks That Are Ticking Portfolio Bombs \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}